Methods of treating a subject for a condition

• US 8,569,277 B2
• Filed: 08/11/2004
• Issued: 10/29/2013
• Est. Priority Date: 08/11/2004
• Status: Active Grant

• Current Assignee: Palo Alto Investors
• Original Assignee: Palo Alto Investors
• Inventors: Yun, Anthony Joonkyoo, Lee, Patrick Yuarn-Bor
• Primary Examiner(s): HUI, SAN MING R
• Application Number:
  US10/917,270
• Publication Number:
  US 20060034847A1
• Time in Patent Office: 3,366 Days
• Field of Search: 514/25, 514/56, 514/4, 514/164, 514/182, 514/556
• US Class Current: 514/182
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61K 38/215 IFN-beta
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/482 Serine endopeptidases (3.4.21)
• CPC Class Codes: A61K 38/49 Urokinase; Tissue plasminogen activator
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods.

Claims

1. A method of simultaneously treating a subject for a blood clotting condition, autonomic dysfunction and an inflammatory condition, said method consisting essentially of:

(a) identifying a cardiovascular condition in said subject;

(b) identifying said blood clotting condition, autonomic dysfunction and inflammatory condition in said subject, wherein at least two of said blood clotting condition, autonomic dysfunction and inflammatory condition result from said cardiovascular condition; and

(c) administering an effective amount of a single anti-inflammatory pharmacologically active agent to said subject to simultaneously treat said subject for said blood clotting condition, autonomic dysfunction and inflammatory condition with said single anti-inflammatory pharmacologically active agent, wherein said anti-inflammatory pharmacologically active agent is a glucocorticoid receptor blocker;

wherein;

said blood clotting condition is coronary artery disease;

said autonomic dysfunction is QT interval prolongation; and

said inflammatory condition is sleep apnea.

2. The method according to claim 1, wherein said glucocorticoid receptor blocker is mifepristone.

3. A method of simultaneously treating a subject for a cardiovascular condition, an arrhythmia and a condition that causes hypoxia, said method consisting of:

(a) identifying said cardiovascular condition, said arrhythmia and said condition that causes hypoxia in said subject; and

(d) administering an effective amount of a glucocorticoid receptor blocker to said subject to simultaneously treat said subject for cardiovascular condition, said arrhythmia and said condition that causes hypoxia in said subject;

wherein said arrhythmia or said hypoxia is a result of said cardiovascular condition and

said blood clotting condition is coronary artery disease;

said autonomic dysfunction is QT interval prolongation; and

said inflammatory condition is sleep apnea.

4. The method according to claim 3, wherein said glucocorticoid receptor blocker is mifepristone.